Funding
Undisclosed · Biotech

Epikast secures financing from Kos Biotechnology Partners

Kos Biotechnology Partners backed the provider of commercial and clinical services for biopharmaceutical companies.

Updated Oct 16, 2026By RoundOS Funding desk

Epikast secured financing from Kos Biotechnology Partners on January 30. The amount and round designation were not disclosed. Epikast provides technology-enabled commercial and clinical services to the biopharmaceutical industry.

Funding history

Undisclosed · This roundUndisclosed

Sources

  1. Epikastprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related